Reshape Lifesciences Inc (NASDAQ:RSLS) shares reached a new 52-week high and low during mid-day trading on Thursday . The company traded as low as $3.10 and last traded at $3.36, with a volume of 3200 shares traded. The stock had previously closed at $3.16.
A number of research firms recently issued reports on RSLS. Zacks Investment Research downgraded Reshape Lifesciences from a “buy” rating to a “sell” rating in a research note on Tuesday. ValuEngine upgraded Reshape Lifesciences from a “sell” rating to a “hold” rating in a research note on Wednesday, May 2nd.
The company has a market cap of $8.76 million, a price-to-earnings ratio of -0.07 and a beta of 2.43.
Reshape Lifesciences (NASDAQ:RSLS) last announced its earnings results on Monday, May 14th. The medical device company reported ($5.40) earnings per share for the quarter. Reshape Lifesciences had a negative net margin of 1,715.25% and a negative return on equity of 69.19%. The company had revenue of $0.95 million during the quarter. equities research analysts expect that Reshape Lifesciences Inc will post -9.15 earnings per share for the current fiscal year.
A hedge fund recently bought a new stake in Reshape Lifesciences stock. Anson Funds Management LP bought a new stake in Reshape Lifesciences Inc (NASDAQ:RSLS) during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The firm bought 219,016 shares of the medical device company’s stock, valued at approximately $324,000. Anson Funds Management LP owned about 0.73% of Reshape Lifesciences at the end of the most recent quarter.
About Reshape Lifesciences
ReShape Lifesciences Inc, a medical device company, focuses on the design and development of devices that use neuroblocking technology to treat obesity, metabolic diseases, and other gastrointestinal disorders. Its proprietary neuroblocking technology, vBloc Therapy is designed to intermittently block the vagus nerve using electrical impulses.
Receive News & Ratings for Reshape Lifesciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Reshape Lifesciences and related companies with MarketBeat.com's FREE daily email newsletter.